Figure 2.

Sorting human and murine ASCs for target specificity. (a) Sort of freshly obtained human plasma blasts for secreted antibodies specific to tetanus toxoid (TT-CTD) via FRET. Decreased green donor and similarly increased red acceptor fluorescence indicate FRET by specific recombinant target binding in the respective droplet. (b) Sort for TT specificity as in (a), applying frozen and revived plasma blasts. (c) Confirmation of mainly sub-nanomolar TT affinities obtained via BLI within 4 weeks from ASC sourcing. (d) Sort of freshly obtained murine plasma cells for secreted antibodies specific for a cancer-related antigen (CRA). (e) Dispensing of sort shown in (d) – binders later confirmed as positive are shown in red, dispensed droplets in light blue, and non-dispensed droplets in gray that were used as a negative reference signal during dispensing. Positions of positive signals confirm appropriate gating. (f) Sort for CRA specificity as in (d), applying frozen and revived plasma cells. Refer to Table 1 for statistics of these antibody hit discovery campaigns